Skip to main content

Table 8 Use of immunomodulatory therapy—antibodies (reciprocal dilution)—by time interval

From: Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals

Categorical time Number of individuals Average time (days) GMT (reciprocal dilution)
CONT (1–5 years) 4 1553 (1200–1800) 375.55
CONT (> 5–9 years) 26 2745 (1950–3240) 179.30
CONT (10 years) 11 3900 (3450–5520) 136.07
cs + bDMARD (1–5 years) 10 1233 (660–1830) 244.88
cs + bDMARD (> 5–9 years) 24 2686 (2070–3420) 126.81
cs + bDMARD (10 years) 13 5268 (3600–7500) 103.25